no NSAID
Phase 3Small molecule
no NSAID is one of 35 small molecule programs targeting Chronic pain. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
193 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Nucynta
CCollegium Pharmaceutical, Inc.
Phase 3
Tramadol Plus Acetaminophen
Johnson & JohnsonPhase 3
Oxycodone CR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Zohydro Er
TevaPhase 3
Dextromethorphan Hydrobromide
Boehringer IngelheimPhase 3
MS Contin
Merck & Co.Preclinical
no NSAID
UUniversity Hospital, Strasbourg, France
Phase 3
Oravescent Fentanyl
CCephalon
Phase 3
Cymbalta
Alnylam PharmaceuticalsPreclinical
Dayvigo
EisaiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for no NSAID. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details